Skip to main content
Caplight Logo









BiPER Therapeutics

BiPER Therapeutics

Private
StrasbourgHealthcare & Life Scienceshttps://biper-tx.com/

Last Round

SAFE

Dec 2, 2025

Total Funding Raised

$3.35M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

BiPER Therapeutics is a biotechnology company that develops first-in-class small molecule therapeutics targeting BiP to treat cancer and other diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

biotechnologydrug discoverysmall moleculeoncologyprecision medicineBiP inhibitorgastrointestinal cancerpreclinical biotechdrug developmentendoplasmic reticulum stressER stresstherapeutic pipelinedrug candidatebiotech startupAI drug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

BiPER Therapeutics Comparables

Compare BiPER Therapeutics with similar companies based on industry and business-model similarity.

BiPER Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
EtiraRx
78%
HiberCell
77%
SPIMA Therapeutics
74%

BiPER Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SAFEDec 2, 2025
Convertible DebtDec 17, 2024
SeedFeb 14, 2023

Key People

Founding team and executive leadership

Mehdi Chelbi

Co-founder and Chief Executive Officer

Founding Team

Stéphane MILOT

Chief Financial Officer

Executive Team

BiPER Therapeutics Investors

Notable investors and investment history

BiPER Therapeutics investors
InvestorRounds
MEDIN VCSAFE
WiSeedConvertible Debt, Seed
BpifranceConvertible Debt, SAFE, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 18, 2026

    Grew 36% QoQ, from 11 to 15 employees.

  • Apr 23, 2026

    Grew 40% QoQ, from 10 to 14 employees.

BiPER Therapeutics Filings

Explore SEC and related filing metadata, where available.

BiPER Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about BiPER Therapeutics's valuation, stock price, and market status.

Is BiPER Therapeutics a public or private company?

BiPER Therapeutics is a private company.

What is the current stock price of BiPER Therapeutics?

BiPER Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is BiPER Therapeutics worth (valuation)?

Valuation information for BiPER Therapeutics is not publicly available.

Can I buy BiPER Therapeutics stock?

BiPER Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was BiPER Therapeutics's last funding round?

BiPER Therapeutics's most recent funding round was SAFE on December 2, 2025.

Who are the main investors in BiPER Therapeutics?

Key investors in BiPER Therapeutics include MEDIN VC.

Will BiPER Therapeutics IPO soon?

No public IPO plans have been announced for BiPER Therapeutics.

How can I track BiPER Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor BiPER Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersStrasbourg
Employee Range11
Year Founded2021
Last FundingDec 2, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?